Clinical development failure
Pipeline value depends on proving safety and efficacy in human trials, which is inherently uncertain in oncology.
- Scope
- Naporafenib and other RAS/MAPK programs
- Materiality
- high
Erasca, Inc.
Erasca, Inc. is a clinical-stage precision oncology company focused on discovering, developing, and commercializing therapies for cancers driven by the RAS/MAPK pathway. Its pipeline is built around targeting key signaling nodes, targeting RAS directly, and blocking escape mechanisms that emerge during treatment.
10.04
10.04
| % | |
|---|---|
| Clinical-stage oncology pipeline | 95% Drug candidates and combination regimens aimed at RAS/MAPK pathway-driven cancers. |
| External innovation and licensing | 3% In-licensed and acquired assets sourced from third parties to expand the pipeline. |
| Corporate venture investments | 2% Minority equity investments in early-stage biotechnology companies through Erasca Ventures. |
Erasca does not currently sell approved products and has no commercial customer base today...
- Future oncology patientsprimary
Patients with NRAS-mutated melanoma and other RAS/MAPK-driven solid tumors who would use approved therapies.
- Oncology treatment centersprimary
Hospitals, cancer centers, and physician groups that would adopt and administer the drugs if approved.
- Research and development partnerssecondary
CROs, CMOs, consultants, and scientific advisors that execute trials and manufacturing work.
- Licensing and collaboration counterpartiessecondary
Biotech and academic partners that provide assets, IP, or commercialization support.
Erasca is headquartered in the United States and currently conducts its business primarily through U.S...
- •United States is the core operating base and first commercialization target
- •Europe is a potential second launch market if approvals are obtained
- •Other regions may be accessed through partnerships rather than direct sales
- •Clinical development is globally sourced through external innovation and partners
- •No disclosed country revenue because the company has no product sales
Erasca’s strategy is to build a focused precision oncology pipeline around the RAS/MAPK pathway and advance it through...
01
Advance naporafenib and other pipeline assets in biomarker-defined trialsshort-term
Clinical proof-of-concept is required to create value and support future approvals.
02
Use precision oncology trial design to accelerate readoutsmedium-term
Adaptive and basket/umbrella studies can improve speed and efficiency in heterogeneous cancers.
03
Expand the pipeline through external innovationmedium-term
In-licensing and acquisition broaden the addressable biology without relying only on internal discovery.
04
Prepare for eventual commercialization in the U.S. and Europelong-term
A commercial infrastructure will be needed if any candidate is approved, and partnerships may reduce launch burden elsewhere.
Erasca is a pre-revenue biotech with a limited operating history, so its value depends on successful clinical...
Financing risk
The company has no product sales and expects to fund operations through equity, debt, or collaborations.
- Scope
- Ongoing R&D and future commercialization build-out
- Materiality
- high
Regulatory approval risk
Even positive clinical data may not translate into approval, delaying or preventing revenue generation.
- Scope
- All product candidates
- Materiality
- high
Third-party manufacturing and vendor dependence
The company relies on CMOs, CROs, and external service providers for development and supply chain execution.
- Scope
- Clinical trials and future product supply
- Materiality
- medium
Cybersecurity and data integrity
Loss or compromise of clinical trial data could delay regulatory filings and increase recovery costs.
- Scope
- Trial data, IP, and vendor systems
- Materiality
- medium
Research and development expense capitalization policy
Quarterly operating results can swing with trial activity and vendor spend
Stock-based compensation
Affects operating expenses and diluted share count
Fair value of marketable securities
Can affect other income and liquidity presentation
License and acquisition accounting
Can affect balance sheet intangibles and future impairment risk
: 28.4.2026